Trial
NCT03807063
Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Fred Hutchinson Cancer Center
Collaborators
National Cancer Institute (NCI); Bellicum Pharmaceuticals
Condition
Acute Bilineal Leukemia
Intervention
Rivogenlecleucel
Why stopped
Insufficient funding
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-08-14